INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← Oncology / Health Desk

Resistant starch in Lynch syndrome: read beyond colorectal cancer

Long-term randomized follow-up found different results for colorectal and other Lynch-associated cancers.

Whole-food ingredients prepared without added oil

Illustrative food image, not a photograph of the study intervention.

A specific trial preparation

The CAPP2 follow-up concerns people with Lynch syndrome and a randomized resistant-starch preparation, not a comparison of ordinary foods. Participants received 30 grams of resistant starch daily or placebo for up to four years. The long-term report included 463 people allocated to resistant starch and 455 allocated to placebo. These are research intervention details, not instructions for recreating treatment at home. Nothing in this abstract establishes that a serving of beans, cooled potatoes, or another resistant-starch food supplies an equivalent exposure or would produce the same clinical outcome in this population.

Mathers JC, Elliott F, Macrae F, Mecklin JP et al.. Cancer prevention research (Philadelphia, Pa.), 2022. PMID 35878732 · DOI

The colorectal result was null

The report presented planned ten-year follow-up, supplemented with cancer-registry information extending to twenty years in England, Wales, and Finland. That does not mean every participant had twenty years of observation. There were 52 participants diagnosed with colorectal cancer in the resistant-starch group and 53 in the placebo group. The investigators reported no difference in colorectal cancer incidence. A headline saying simply that resistant starch prevented cancer would hide this central distinction. The trial cannot be presented as demonstrating colorectal cancer prevention when its long-term colorectal comparison did not show that result.

Mathers JC, Elliott F, Macrae F, Mecklin JP et al.. Cancer prevention research (Philadelphia, Pa.), 2022. PMID 35878732 · DOI

A different signal outside the colorectum

Non-colorectal Lynch-associated cancers occurred in 27 participants allocated to resistant starch and 48 allocated to placebo. The intention-to-treat hazard ratio was 0.54, with a 95% confidence interval of 0.33 to 0.86. The authors also highlighted upper gastrointestinal cancers, with five diagnoses in the resistant-starch group and twenty-one in the placebo group. Those diagnosis counts should not be confused with the broader counts of participants affected. The result is therefore endpoint-specific: a favorable non-colorectal cancer signal alongside a null colorectal cancer result in the same long-term trial report.

Mathers JC, Elliott F, Macrae F, Mecklin JP et al.. Cancer prevention research (Philadelphia, Pa.), 2022. PMID 35878732 · DOI

Keep the population and product attached

Randomization supports interpretation of the assigned preparation more strongly than an observational comparison of eating habits would. It does not erase the specificity of Lynch syndrome, the tested product, or the follow-up structure. The findings do not establish a general-population cancer-prevention menu, prove that all resistant-starch products are interchangeable, or quantify the value of an individual food. This article deliberately links no recipe and offers no substitute dosing schedule. The useful reading habit is to retain both cancer categories in the summary and to distinguish a trial preparation from foods that merely share a nutrient label.

Mathers JC, Elliott F, Macrae F, Mecklin JP et al.. Cancer prevention research (Philadelphia, Pa.), 2022. PMID 35878732 · DOI